Threshold Pharmaceuticals Announces Preclinical Multiple Mye
Publicado: Mar Dic 08, 2009 10:52 am
Threshold Pharmaceuticals Announces Preclinical Multiple Myeloma Data
http://money.cnn.com/news/newsfeeds/art ... 179830.htm
Fuente.
CNNMoney.com
December 07, 2009: 04:00 PM ET
REDWOOD CITY, Calif., Dec. 7, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced preclinical results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented today at the American Society of Hematology (ASH) Meeting being held December 5 to 8, 2009, in New Orleans, LA.
Cita:
""Hypoxia is known to be linked to increased metastatic potential and poorer disease outcomes," said Karin Vanderkerken, Ph.D., Department of Hematology and Immunology-Myeloma Center Brussels, Belgium. "This study has demonstrated that hypoxia exists in the bone marrow in an established model of myeloma and, importantly, TH-302 has had an impressive treatment effect in this preclinical model."
Hypoxia is known to be associated with poor prognosis and tumor progression in solid tumors. Scientists have also been studying the effects of hypoxia on hematopoetic stem cells in the bone marrow. Thus, a preclinical study was undertaken to evaluate the hypoxic condition in the bone marrow in a murine model of multiple myeloma (MM), the 5T33MM syngeneic model, using the hypoxia-activated prodrug, TH-302.
The study found that almost all of the MM cells in the model reside in a hypoxic environment in the bone marrow and that these tumor cells may be a target for tumor-specific treatment with TH-302. In vivo, animals treated prophylactically with TH-302 showed decreased serum paraprotein compared to those not treated with TH-302. The frequency of apoptotic MM cells in bone marrow sections was also significantly increased in animals treated with TH-302. In vitro, 5T33 cell-based assays demonstrated TH-302 induces cell cycle arrest and triggers apoptosis in an oxygen concentration-dependent manner. Taken together, these results support continued investigation with TH-302 as a potential treatment for multiple myeloma.
A copy of the poster may be obtained by calling the Company."
fin de la cita.
saludos
http://money.cnn.com/news/newsfeeds/art ... 179830.htm
Fuente.
CNNMoney.com
December 07, 2009: 04:00 PM ET
REDWOOD CITY, Calif., Dec. 7, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced preclinical results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented today at the American Society of Hematology (ASH) Meeting being held December 5 to 8, 2009, in New Orleans, LA.
Cita:
""Hypoxia is known to be linked to increased metastatic potential and poorer disease outcomes," said Karin Vanderkerken, Ph.D., Department of Hematology and Immunology-Myeloma Center Brussels, Belgium. "This study has demonstrated that hypoxia exists in the bone marrow in an established model of myeloma and, importantly, TH-302 has had an impressive treatment effect in this preclinical model."
Hypoxia is known to be associated with poor prognosis and tumor progression in solid tumors. Scientists have also been studying the effects of hypoxia on hematopoetic stem cells in the bone marrow. Thus, a preclinical study was undertaken to evaluate the hypoxic condition in the bone marrow in a murine model of multiple myeloma (MM), the 5T33MM syngeneic model, using the hypoxia-activated prodrug, TH-302.
The study found that almost all of the MM cells in the model reside in a hypoxic environment in the bone marrow and that these tumor cells may be a target for tumor-specific treatment with TH-302. In vivo, animals treated prophylactically with TH-302 showed decreased serum paraprotein compared to those not treated with TH-302. The frequency of apoptotic MM cells in bone marrow sections was also significantly increased in animals treated with TH-302. In vitro, 5T33 cell-based assays demonstrated TH-302 induces cell cycle arrest and triggers apoptosis in an oxygen concentration-dependent manner. Taken together, these results support continued investigation with TH-302 as a potential treatment for multiple myeloma.
A copy of the poster may be obtained by calling the Company."
fin de la cita.
saludos